On Friday, Shares of AbbVie Inc (NYSE:ABBV), lost -1.12% to $55.74.
AbbVie (ABBV) will take part in the 34th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 13, 2016. Richard A. Gonzalez, chairman and chief executive officer, will make a formal presentation on the company at 10:30 a.m. Central time.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products comprise HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, counting those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants.
Shares of Rite Aid Corporation (NYSE:RAD), declined -0.51% to $7.84, during its last trading session.
Rite Aid Corporation (RAD), stated operating results for its fiscal third quarter ended November 28, 2015. The company stated revenues of $8.2 billion, net income of $59.5 million or $0.06 per diluted share, and Adjusted EBITDA of $373.2 million, or 4.6 percent of revenues.
“We are happy with our results for the third quarter, which reflect growth in revenue, same-store sales and Adjusted EBITDA together with positive, noteworthy contributions from our new Pharmacy Services Segment,” said Rite Aid Chairman and CEO John Standley. “We also continued making tremendous progress in strengthening our retail healthcare offering by converting additional stores to our Wellness format. We thank our dedicated Rite Aid team for their continued hard work in executing our key initiatives and serving our valued customers.”
Third Quarter Summary
Revenues for the quarter were $8.2 billion as contrast to revenues of $6.7 billion in the prior year’s third quarter, an improvement of $1.5 billion or 21.8 percent. Retail Pharmacy Segment revenues were $6.7 billion and raised 0.8 percent contrast to the prior year period primarily as a result of an improvement in same store sales. Pharmacy Services Segment revenues were $1.5 billion.
Same store drugstore sales for the Retail Pharmacy Segment raised 0.9 percent over the prior year, comprising of a 0.3 percent improvement in front-end sales and a 1.2 percent improvement in pharmacy sales. Pharmacy sales comprised an approximate 252 basis point negative impact from new generic introductions. The number of prescriptions filled in same stores raised 0.2 percent over the prior year period. Prescription sales accounted for 69.9 percent of total drugstore sales, and third party prescription revenue was 97.9 percent of pharmacy sales.
Net income was $59.5 million or $0.06 per diluted share contrast to last year’s third quarter net income of $104.8 million or $0.10 per diluted share. The decline in net income was due to lower income tax expense in the prior year as a result of an adjustment to the company’s deferred tax valuation allowance of $45.9 million, an improvement in interest and amortization expense related to the company’s purchase of EnvisionRx and transaction expenses of $9.8 million related to the company’s pending merger with Walgreens Boots Alliance, Inc. (“WBA”). These items were partially offset by an improvement in Adjusted EBITDA and a prior year loss on debt retirement.
Rite Aid Corporation, through its auxiliaries, operates a chain of retail drugstores in the United States. The company sells prescription drugs and a range of other merchandise, counting over-the-counter medications, health and beauty aids, personal care items, cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, and other every day and convenience products.
Finally, United States Steel Corporation (NYSE:X), ended its last trade with 7.81% gain, and closed at $8.01.
United States Steel Corporation, declared a tentative agreement with the United Steelworkers (USW) on a successor three-year collective bargaining agreement covering about 18,000 USW-represented employees at U. S. Steel’s domestic flat-rolled and iron ore mining facilities in addition to tubular operations in Fairfield, Ala., Lorain, Ohio and Lone Star, Texas. The tentative agreement remains subject to ratification.
“We are happy that we have reached a tentative agreement in the best interest of our company, our stakeholders and our employees,” said Mario Longhi, President and Chief Executive Officer. “We believe this competitive three-year contract further supports the mutual success we have had with the USW in pursuing our Carnegie Way efforts and confronting unfair trade that is significantly impacting our industry.”
United States Steel Corporation produces and sells flat-rolled and tubular steel products in North America and Europe. It operates through three segments: Flat-Rolled Products (Flat-Rolled), U. S. Steel Europe (USSE), and Tubular Products (Tubular). The Flat-Rolled segment offers slabs, rounds, strip mill plates, sheets, and tin mill products.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
